pharmacie et médicaments – Développement des biosimilaires

This written question concerns the development of biosimilar medicines in France. It seeks to understand the current state of policies and initiatives aimed at promoting their use and accessibility. The question likely affects patients, healthcare providers, and pharmaceutical companies, potentially impacting treatment costs and therapeutic options.